Latest news with #AstraZenecaPLC
Yahoo
5 days ago
- Business
- Yahoo
Summit, AstraZeneca (AZN) in Advanced Talks Over $15 billion Oncology Licensing Deal
AstraZeneca PLC (NASDAQ:AZN) is one of the best high growth stocks. Bloomberg reported on July 3 that AstraZeneca is engaged in negotiations with Summit Therapeutics Inc. (NASDAQ:SMMT) regarding a potential licensing agreement for an experimental lung cancer therapy, with the deal valued at up to $15 billion. According to Bloomberg News, the potential deal may feature a multi-billion-dollar upfront payment to Summit along with subsequent milestone payouts. Nonetheless, the negotiations could collapse, or Summit may choose an alternative licensing collaborator. The talks pertain to ivonescimab, a drug Summit gained access to under a separate December 2022 agreement with Chinese firm Akeso, worth up to $5 billion. A pharmacy worker distributing prescription medicines to patientsreceiving treatment for oncology, cardiovascular, renal, metabolism and respiratory diseases. The company reported in May that ivonescimab, when used alongside chemotherapy in a Phase III trial, showed a favorable survival signal, but fell short of delivering a statistically significant outcome. Earlier findings from 2023 suggested that some patients with lung cancer had higher survival rates on the investigational drug than on Merck's widely used Keytruda. AstraZeneca PLC (NASDAQ:AZN) is a global biopharmaceutical company involved in the discovery, development, manufacturing, and commercialization of prescription medicines across a range of therapeutic areas, including oncology, cardiovascular, renal and metabolic diseases, respiratory and immunology, vaccines, and rare diseases. While we acknowledge the potential of AZN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure. None.
Yahoo
5 days ago
- Business
- Yahoo
AstraZeneca PLC (AZN) Partners Modella AI for AI Drug Development
AstraZeneca PLC (NASDAQ:AZN) is one of the 10 best defensive stocks to buy in a volatile market. On July 4, the company entered into a multi-year agreement with Modella AI. The two are joining forces to accelerate AI-driven clinical development in oncology. A closeup view of a magnified pharmaceutical tablet. As part of the strategic partnership, AstraZeneca is to gain access to Modella AI's multi-modal foundation models. The models feature rich data extraction from various types of data to accelerate the clinical development of the oncology portfolio. 'Through the use of foundation models, combined with our unique datasets and AI expertise, we are confident in our strategy to accelerate development and increase the probabilities of success in our oncology clinical trials,' AstraZeneca oncology research and development (R&D) chief AI and data scientist Jorge Reis-Filho stated. AstraZeneca plans to leverage AI models for cancer research and development capabilities to enhance discovery and clinical development. AstraZeneca PLC (NASDAQ:AZN) is a science-led biopharmaceutical company that focuses on the research, development, and commercialization of prescription medicines. It develops medicines for diseases in the areas of oncology, cardiovascular, renal, metabolism, respiratory, immunology, and rare diseases. While we acknowledge the potential of AZN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
01-07-2025
- Business
- Yahoo
AstraZeneca stock rises amid reports CEO favors US listing move
-- AstraZeneca PLC (NASDAQ:AZN) ADRs rose 2.2% following a Times report that CEO Sir Pascal Soriot has privately expressed interest in moving the company's stock market listing to the United States. According to The Times, citing sources familiar with his thinking, Soriot has discussed his preference for relocating the FTSE 100 company's listing on multiple occasions and has even considered moving AstraZeneca's domicile. However, such a move would likely face resistance from parts of the board and the British government, which reportedly has not been informed of these discussions. Soriot, who has led the pharmaceutical giant since 2012, has publicly voiced concerns about Europe falling behind the US and China in developing innovative medicines. These two markets represent AstraZeneca's largest revenue sources globally. The CEO is reportedly "deeply frustrated" with the UK's operating environment, particularly regarding restrictions on new medicine approvals by the National Institute for Health and Care Excellence (Nice). Specific concerns include approval challenges for drugs and pricing constraints under the NHS sales rebate scheme. As Britain's most valuable public company, any potential move by AstraZeneca would represent a significant shift in the UK corporate landscape. The company has become a cornerstone of the British pharmaceutical industry under Soriot's leadership over the past decade. Related articles AstraZeneca stock rises amid reports CEO favors US listing move INmune slides again as Scotiabank, RJ cut ratings after Alzheimer's drug miss Wolfe Research refreshes high-conviction ideas heading into H2 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
30-06-2025
- Business
- Yahoo
AstraZeneca (AZN) Announces Strategic Research Collaboration with CSPC Pharmaceuticals
AstraZeneca PLC (NASDAQ:AZN) is one of the 11 Best Strong Buy Stocks to Invest in Now. On June 13, AstraZeneca PLC (NASDAQ:AZN) announced that it had entered into a strategic research collaboration with CSPC Pharmaceuticals Group Limited, based in Shijiazhuang City. The research collaboration aims to discover and develop novel oral candidates with the hopes of treating diseases across multiple indications. A pharmacy worker distributing prescription medicines to patientsreceiving treatment for oncology, cardiovascular, renal, metabolism and respiratory diseases. Under the agreement, the two companies will discover and develop pre-clinical candidates for various targets related to the treatment of diseases across chronic indications. This includes a pre-clinical small molecule oral therapy for immunological diseases. CSPC would conduct the research in Shijiazhuang City, utilizing its AI-driven, dual-engine efficient drug discovery platform. The collaboration is expected to expand AstraZeneca PLC's (NASDAQ:AZN) presence in China following the announcement of a $2.5 billion investment to develop a new global strategic R&D center in Beijing earlier in the year. AstraZeneca PLC (NASDAQ:AZN) is a biopharmaceutical company that explores, develops, manufactures, and commercializes prescription medicines. It supplies its products and services to specialty and primary care physicians. AstraZeneca PLC (NASDAQ:AZN) distributes its products and services through local representative offices and distributors. While we acknowledge the potential of AZN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
30-05-2025
- Business
- Yahoo
Danaher Corporation (DHR) Launches Partnership with AstraZeneca PLC (AZN) to Scale Next-Gen Precision Medicine Tests
Danaher Corporation (NYSE:DHR) and AstraZeneca PLC (NASDAQ:AZN) have announced a major partnership to accelerate the development and commercialization of advanced diagnostic tools aimed at expanding precision medicine. Leveraging DHR's newly launched Centers for Enabling Precision Medicine, the collaboration will focus on creating AI-powered diagnostics to help clinicians better identify which patients are most likely to benefit from targeted therapies, such as next-generation antibody-drug conjugates. A handshake between two men in the lobby of a modern office building, signifying the formation of a Master Limited Partnership. The partnership's first initiative will utilize technologies from Leica Biosystems, a Danaher Corporation (NYSE:DHR) subsidiary renowned for its digital pathology solutions. The initial emphasis will be on digital and computational pathology products and AI-assisted algorithms, aiming to improve diagnostic accuracy and patient selection for precision treatments. Leica Biosystems is also committed to advancing interoperability in clinical workflows through open-access DICOM standards. Danaher Corporation (NYSE:DHR) Executive Vice President Julie Sawyer Montgomery highlighted the goal of increasing access to precision medicines so that no patients are left behind, while AstraZeneca PLC (NASDAQ:AZN)'s Susan Galbraith underscored the critical role of AI-based diagnostics in matching patients with the most effective therapies. Both companies view this collaboration as a significant step toward global digital transformation in pathology and a milestone in delivering personalized healthcare solutions worldwide While we acknowledge the potential of DHR to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than DHR and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None. Sign in to access your portfolio
